ライフサイエンスコーパス: FACIT

1 FACIT-F and the Edmonton Symptom Assessment System (ESAS

2 FACIT-F and/or the Edmonton Symptom Assessment System (E

3 FACIT-Fatigue scores improved from baseline to day 28 (m

4 nce interval [CI]: 0.94 to 18.05, p = 0.030; FACIT-Pal difference = 11.77 points, 95% CI: 0.84 to 22.

5 mean difference, 0.20; 95% CI, 0.06 to 0.34; FACIT-Pal mean difference, 4.94), whereas the associatio

6 mean difference, 0.46; 95% CI, 0.08 to 0.83; FACIT-Pal mean difference, 11.36] and symptom burden at

7 e results demonstrate a novel function for a FACIT collagen in guiding vertebrate motor axons through

8 with interrupted triple-helices (FACIT) and FACIT-like (types XII, XIV, and XX), network-forming (ty

9 L and FT were evaluated using the FACT-G and FACIT-COST tools, respectively.

10 pectively, and improvements in hemolysis and FACIT-fatigue scale scores were maintained.

11 nificant incremental improvement in KCCQ and FACIT-Pal scores from randomization to 6 months (KCCQ di

12 tory, Edmonton Symptom Assessment Scale, and FACIT Spiritual Well-Being subscale; at 6 months, advanc

13 h interrupted triple helices, referred to as FACITs, contributes to the differences in the BM zones o

14 py was the zebrafish homolog of the atypical FACIT collagen collagenXIXa1 (colXIX).

15 venty-seven were allocated placebo (baseline FACIT-F = 22 [SD, 10]); 82 were allocated methylphenidat

16 lth-related quality of life (demonstrated by FACIT-F, HAQ DI, and SF-36 scores, respectively) and sho

17 ificant difference in fatigue improvement by FACIT-F (P = .31) or ESAS (P = .14) between groups.

18 ificant difference in fatigue improvement by FACIT-F (P = .57) or ESAS (P = .18) between groups.

19 l financial hardship (denoted by median COST-FACIT score <27 points) was reported by 49% (95% CI, 44%

20 nancial hardship was assessed using the COST-FACIT (Comprehensive Score for Financial Toxicity-Functi

21 .5 +/- 2.2 v 2.8 +/- 2.1 (P <.001); fatigue (FACIT-F) subscore, 17.5 +/- 11.3 v 34.7 +/- 10.0 (P <.00

22 ional Assessment of Chronic Illness-Fatigue (FACIT-F) subscale from baseline to day 15.

23 p had significantly lower levels of fatigue (FACIT) at the end of radiotherapy (z, 6.73; P < .001), 4

24 sessment of chronic illness therapy fatigue (FACIT-F) scale, the Hamilton rating scale for depression

25 sessment of Chronic Illness Therapy Fatigue (FACIT-F) scores between groups at 6 +/- 2 weeks.

26 sessment of Chronic Illness Therapy-Fatigue (FACIT-F) fatigue subscale.

27 essment for Chronic Illness Therapy-Fatigue (FACIT-F) was performed at baseline, day 7, and day 28.

28 sessment of Chronic Illness Therapy-Fatigue (FACIT-F), Dehydration Assessment Scale, creatinine, urea

29 sessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire (HAQ) Disabili

30 sessment of Chronic Illness Therapy-Fatigue (FACIT-F), the Chronic Liver Disease Questionnaire-HCV Ve

31 essment for Chronic Illness Therapy-Fatigue (FACIT-F).

32 sessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), and Physicians Global Assessment (PGA) i

33 sessment of Chronic Illness Therapy-Fatigue [FACIT-F], Chronic Liver Disease Questionnaire-HCV (CLDQ-

34 o differences between arms were observed for FACIT-Fatigue or other toxicities.

35 d collagens with interrupted triple-helices (FACIT) and FACIT-like (types XII, XIV, and XX), network-

36 d collagens with interrupted triple helices (FACITs) differs from that of fibrillar collagens that ha

37 d collagens with interrupted triple helices (FACITs) must differ from that of fibrillar collagens, si

38 ad increased odds of having moderate to high FACIT-COST scores compared with those who never had LC (

39 imary end point was the median difference in FACIT-F fatigue at day 15.

40 ant differences in the median improvement in FACIT-F fatigue between the MP and PL groups (5.5 v 6.0,

41 The improvement in FACIT-F total quality-of-life scores was also significan

42 Clinically meaningful improvements in FACIT-Fatigue scores were observed at 48 weeks, with a m

43 Results for day 7, including FACIT-F, were similar.

44 Hb levels, reduced hemolysis, and increased FACIT-fatigue scale scores in the first weeks; at week 4

45 lly meaningful improvements in fatigue (mean FACIT-F improvement 5.0 vs 1.9; p<0.0001, difference 3.0

46 Median FACIT-F fatigue scores improved from baseline to day 15

47 SD, 10]); 82 were allocated methylphenidate (FACIT-F = 20 [SD, 9]).

48 The influence of FACIT collagen XII and XIV deficiency on the morphology,

49 The NC2 domain (only 35-50 residues) of FACIT collagens is a potent trimerization domain.

50 terotrimeric collagen IX, the only member of FACITs with all three chains encoded by distinct genes.

51 trimerizing role for the NC2 domain in other FACITs.

52 domain of collagen XIX and probably of other FACITs is responsible for chain selection and trimerizat

53 proved in UC + PAL versus UC-alone patients (FACIT-Sp difference = 3.98 points; p = 0.027).

54 ronic Illness Therapy-palliative care scale (FACIT-Pal) instrument (range, 0-184 [worst-best]; minima

55 ronic Illness Therapy-Palliative Care scale (FACIT-Pal), assessed at 6 months.

56 ed via the FACIT-Spiritual Well-Being scale [FACIT-Sp]), hospitalizations, and mortality.

57 Across 10 weeks of the study, FACIT-F was nominally higher in the methylphenidate grou

58 illness measurement system fatigue subscale (FACIT-F), a validated assessment of fatigue and its seve

59 The FACIT-F fatigue subscale score on day 8 was considered t

60 The FACIT-F fatigue subscore on day 8 was considered the pri

61 (+/- standard deviation) improvement in the FACIT-F subscale at day 15 was significantly higher in t

62 Baseline fatigue scores in the FACIT-Fatigue instrument improved by 12.2 +/- 1.1 points

63 Chick cDNA clones for a new member of the FACIT (fibril-associated collagens with interrupted trip

64 ome 6q12-q13, very close to the locus of the FACIT collagen genes COL9A1 and COL19A1.

65 tations in the COL12A1 gene, a member of the FACIT collagens (fibril-associated collagens with interr

66 Assignment of type XX collagen to the FACIT family was based on sequence similarities to types

67 DS]), spiritual well-being (measured via the FACIT-Spiritual Well-Being scale [FACIT-Sp]), hospitaliz

68 ional Assessment of Chronic Illness Therapy (FACIT) -Fatigue score from baseline to 28 days, adjusted

69 ional Assessment of Chronic Illness Therapy (FACIT) -Fatigue subscale and Visual Analog Scales (VASs;

70 ional Assessment of Chronic Illness Therapy (FACIT) General quality of life (QOL) scale (primary outc

71 ional assessment of chronic illness therapy (FACIT)-fatigue scale.

72 ional Assessment of Chronic Illness Therapy (FACIT-COST), and work impact was measured using the Work

73 ional Assessment of Chronic Illness Therapy [FACIT] -Fatigue), and NTX grade.

74 ional Assessment of Chronic Illness Therapy [FACIT]-Fatigue scale) was assessed in the intention-to-t

75 itive decline in a placebo-controlled trial [FACIT (Folic Acid and Carotid Intima-media Thickness)].

76 After 6 +/- 2 weeks, FACIT-F scores were 1.97 points (95% CI, -0.95 to 4.90;